1/105
Looks like no tags are added yet.
Medication classes for AD
-Cholinesterase inhibitors
-NMDA receptor antagonist
-Combo
-Anti-amyloid monoclonal antibody therapy
Cholinesterase inhibitors
-Donepezil (patch)
-Galantamine
-Rivastigmine (patch available)
NMDA antagonists
-Memantine
Combo drug
-Memantine/donepezil
Anti-anyloid monoclonal antibody therapy
-Lecanemab
-Donanemab
Goals of therapy
-There is no cure
-Delaye disease progression and preservation of functioning as long as possible
-Treating psychiatric and behavioral symptoms that may occur during the course of the disease
General pathophys
-Abnormal proteins
-Decreased NTs
-Genetics
Abnormal proteins
-High amyloid-beta plaques and tau tangles
-Both cause neurodegeneration
NTs in AD
-Ach
-Glutamate
Ach in AD
-Plaques and tangles damage acetylcholine
-Shortage of Ach impairs learning and memory
-This is the background for treatment with acetylcholinesterase inhibitor
Glutamate in AD
-Primary excitatory NT
-Involved in memory, learning, and neuronal plasticity
-Glutamate receptor N-methyl-D-aspartate (NMDA) is less prevalent in AD
-Overactivation of unregulated glutamate signaling
-Rise in Ca ions that induce secondary cascades, leading to neuronal death and increased APP causing more plaques and tangles
Early onset AD
-AD prior to age 60
-Approx 1% of AD
-Usually familial: autosomal dominant
Late onset AD
-Genetic susceptibility is more sporadic
-More dependent on environment
-Apo E gene on chromosome 19: strong risk factor for late onset
Symptoms of mild neurocognitive disorder
-Mild decline in cognitive function and modest impairment in cognitive performance (usually via testing)
-Don't interfere with everyday activities
Symptoms of moderate neurocognitive disorder
-Significant decline in cognitive function and substantial impairment in cognitive performance (usually via testing)
-Interfere with independence in everyday activities
Diagnostic criteria for AD
-Criteria met for neurocognitive disorder
-Insidious onset, gradual progression
-Clear evidence of decline
-Steadily progressive without plataues
-Major: Evidence of genetics, probable AD diagnosed
-Mild: possible AD diagnosed
When to initiate pharm therapy
-ASAP after diagnosis
Treatment for mild AD
-Acetylcholinesterase inhibitor
Treatment for moderate-to-severe AD
0Acetylcholinesterase inhibitor, memantine, or combo
Expectations from pharm therapy
-Emphasis should be on helping to maintain a therapeutic living environment while minimizing the burden of care resulting from the disease
When to use antibody therapy
-After confirmation of the presence of amyloid beta pathology and obtainment of a recent brain MRI
-Can be done with mild cognitive impairment
Unconventional AD treatments
-Vitamin E: at
Lifestyle mods
-Music
-Videos of family
-Audiotapes of caregivers
-Walking and light exercise
-Sensory stimulation and relaxation
Behavioral and psychological symptoms of AD
-Agitation
-Aggression
-Anxiety
-Psychosis
Medications for behavioral and psychological symptoms
-See if AChE inhibitors work
-Antipsychotics: brexpiprazole (increased mortality with other antipsychotics)
-Anticonvulsants (conflicting evidence)
-Buspirone
-Selegiline (not well tolerated)
-Trazodone (good for sundowning)
Medication class for depression in AD
-SSRIs
-Avoid anticholinergic antidepressants
Benzos in AD
-For anxiety, agitation, and aggression
-Concern of fall risk
Length of trial for AChE inhibitors
-Need to allow a trial for effectiveness for 3-6 months
-
Common AChE inhibitor adverse effects
-N/V/D
-Headache
-Dizziness
-Muscle cramps
-Insomnia
-Fatigue
-Anorexia
-Depression
Major AChE inhibitor adverse effects
-Anorexia
-Weight loss
-Falls
-Hip fractures
-Syncope
-Bradycardia
-Increased use of cardiac pacemakers
If intolerability
-Shoulds witch from one AChE to another AChE
ARIA
-Brain edema (ARIA-E)
-Microhemorrhage (ARIA-H)
-Detected through monitored imaging
-Symptoms can include headaches, vomiting, confusion, gait disturbance
ARIA monitoring
-MIR required if receiving antibody therapy
Donepezil adverse effects
-N/V/D
-Headache
-Dizziness
-Muscle cramp
-Insomnia
-Fatigue
-Anorexia
-Depression
-Weird dreams
-Weight decrease
Donepezil titration
-Starting: 5 mg in evening
-Maintenance: 5-23 mg
-Adjust over months
-No adjustment for renal/hepatic
Galantamine adverse effects
-N/V/D
-Headache
-Dizziness
-Insomnia
-Fatigue
-Anorexia
-Depression
-Abdominal pain
Galantamine titration
-Starting: 4 BID if IR, 8 daily if ER
-Maintenance: 8-12 BID if IR, 16-24 daily if ER
-Titrate every 4 weeks
Galantamine Pkinetics
-Don't exceed 16 mg for moderate hepatic or renal impairment
-Dont administer in severe hepatic or renal impairment
Rivastigmine adverse effects
-N/V/D
-Headache
-Dizziness
-Insomnia
-Fatigue
-Anorexia
-Depression
-Weight decrease
-Abdominal pain
Rivastigmine titration
-Starting: 1.5 BID (oral), 4.6mg daily (patch)
-Maintenance: 3-6 BID (oral), 9.5 daily (patch
-Oral: titrate over 2 weeks
-Patch: titrate over 4 weeks
Rivastigmine Pkinetics
-Max dose 4.6 mg/day if moderate to severe renal impairment or mild-moderate heapatic impairment or low body weight (
Memantine adverse effects
-V/D
-Headache
-Dizziness
-Fatigue
-Depression
-Abdominal pain
Memantine titration
-Starting: 5m daily IR or 7 mg daily ER
-Maintenance: 10 mg BID IR or 28 mg daily Er
-Over 1 week
Memantine Pkinetics
-Don't exceed 14 mg daily (or 5 mg BID) in severe renal impairment
Antibody therapy adverse effects
-Diarrhea
-Headache
-ARIA-E or H
-Falls
-Infusion related reactions
-Cough
-Confusion
Antibody therapy titration
-10 mg/kg every 2 weeks
-No titration necessary
-No change in renal/hepatic impairment
Drug classes for PD
-Anticholinergics
-MAO-B inhibitors
-Amantadine
-DA agonists
-Sinimet
-COMT inhibitors
-Combo
-Istradefylline
-Pimavanserin
-Droxidopa
Anticholinergics
-Benztropine
MAO-B inhibitors
-Safinamide
-Selegiline
-Rasagiline
DA inhibitors
-Ropinirole
-Rotigotine
-Pramipexole
-Apomorphine
COMT inhibitors
-Tolcapone
-Entacapone
-Opicapone
Primary NT affected
-Decrease in DA in the s. nigra for movement
Primary NT target for PD for drug therapy
-DA
Drugs that can cause drug-induced PD
-Antipsychotics
-Metoclopramide
-Antiemetics
3 cardinal motor findings for PD
-Tremors at rest
-Rigidity
-Akinesia/bradykinesia
-Bonus: postural instability
Common nonmotor symptoms in PD
-Depression, anxiety
-Impulse control
-Paranoia, delusions, visual hallucination
-Constipation, gastroparesis, dysphagia
-Sleep
-Sensory
-Speech symptoms
When should PD medications be initiated
-When symptoms become bothersome
Health care members important in PD
-Dietician
-Speech therapist
-PT or OT
DIetician in PD
-Recommend appropriate caloric intake, meal selection, and protein consumption
-Improves constipation, nausea, weight maintenance, aspiration risk
-Minimizes erratic drug absorption
Speech therapist in PD
-Swallowing, speech volume and articulation, facial expression
-Minimize risk of aspiration and improve communication
PT and OT in PD
-Posture, balance, strength, gait, stamina
-Increases physical activity and reduces fall risk
-Maximize independence at home
Medication for initial treatment of motor symptoms
-Levodopa
When to consider DA or MAO-B
-DA:
Older pts
-Should not receive DA if they have hx of impulse control disorder, cognitive impairment, excessive daytime sleepiness, or hallucinations
Levodopa formulations
-CR
-IR
-ER
-Enteral suspension
-Dry powder
CR levodopa
-Less bioavailable
-Longer and more erratic absorption time (2 hours)
-Not interchangeable with IR, but can be added to extend duration
IR levodopa
-More bioavailable
-30 min absorption time
-Not interchangeable with CR
ER levodopa
-More sustained release
-Peaks within 1 hour and is maintained for 4-5 hrs before declining
-Conversion between CR and IR and ER may be imprecise
Enteral suspension levodopa
-Can administer directly into duodenum via tube
-Improves motor fluctuations
-Reserved for advanced PD and severe motor fluctuations
Dry powder levodopa
-Breath actuated inhaler
-Doesn't require drug absorption in GI tract
-Delivered via lung
-Used for intermittent off periods
-Acts within 10 mins and lasts at least 1 hour
-Use up to 5 times daily
Types of OFF episodes
-Wearing off
-Unpredictable off
-Peak-dose dyskinesia
-Off period dystonia
Wearing off
-When carbidopa/levodopa isn't working as well, typically at the end of the dose schedule
Peak dose dyskinesia
-When levodopa is at its maximal efficacy
-Excessive involuntary movements (chorea or dystonia)
How to manage OFF episodes
-Increase dose and frequency of levodopa, but often limited by development of dyskinesias
-Crush and swallow extra 1/2 tab of levodopa right before next dose
-Add COMT, MAOB, DA, istradefylline, or amantadine
-Unique L-dopa formulations
PD depression
-Common (35% or more), possible premotor sign
-TCAs, SSRIs
-Pramipexole!
PD dementia
-80% mof pts after 20 yrs of diagnosis
-Rivastigmine
PD psychosis
-Gradually decrease and stop low-efficacy antiparkinsonian medications
-If this fails, may consider antipsychotics, but will worsen PD
-Pimavanserin!
-Clozapine and quetiapine!
PD sleep problems
-Amantadine and selegiline may worsen insomnia
-Some antidepressants and antipsychotics may worsen RLS
-Rotigotine patch for sleep
-Sleep hygiene
-Doxepin
PD hypotension
-Orthostatic hypotension common
-Droxidopa: NE synthetic precursor
Common side effects of all anti-PD
-N/V
-Hypotension
-Hallucinations
Benztropine MOA
-Anticholinergic
Benztropine dosing notes
-Good for tremor and drooling, but not other symptoms
-Not for elderly
Benztropine adverse effects
-Anything anticholinergic
Selegiline MOA
MAO-B inhibitor
Selegiline dosing notes
-Mild symptomatic benefit as monotherapy
-Manage motor fluctuations and reduce off time with levodopa
Selegiline adverse effects
-Jitteriness
-Insomnia
-Not wel tolerated
Rasagiline MOA
MAO-B inhibitor
Rasagiline dosing notes
-Mild symptomatic benefit as monotherapy
-Manage motor fluctuations and reduce off time with levodopa
Rasagiline adverse effects
-Less likely to cause insomnia
-No tyramine foods (HTN crisis)
Amantadine MOA
-NMDA antagonist that blocks glutamate transmission and promotes DA release
Amantadine dosing notes
-Effective as mono and adjunct therapy for OFF time and levodopa dyskinesias
-ER specifically for dyskinesias
Amantadine adverse effects
-Livedo reticularis
-Peripheral edema
-Restlessness
-Anticholinergic
-Insomnia (better with ER)
D2 agonist dosing notes
-Monotherapy in early PD and as an adjunct to levodopa in advanced cases
D2 agonist adverse effects
-Sedation
-Pedal edema
-Nightmares
-Confusion
-Daytime sleepiness
-Sudden sleep attacks
-ICD
-DDS
-Apomorphine: severe N/V, must premedicate with antiemetic
ICD
-Impulse control disorders
-Gambling, compulsive shopping and sex, excessive hobbying, binge eating
DDS
-DA dysregulation syndrome
-Drug seeking and punding
Punding
-Repetitive handling and examining of mechanical objects
Carbidopa/levodopa MOA
-Levodopa is a precursor of dopamine
-Carbidopa inhibits dopa decarboxylase preventing peripheral metabolism of levodopa
Carbidopa/levodopa dosing notes
-At least 75 mg/day for effectiveness
-Start at very low dose
-May dose q2h in advanced PD
Carbidopa/levodopa adverse effects
-Anorexia
-Discoloration of urine/sweat
-Minimize by taking with low-protein food or slow titration
-Dyskinesias
-Sleep attachs
-ICDs
-Nightmares
-Confusion